07:00 , May 18, 2015 |  BC Week In Review  |  Company News

Evolva Holding, Emergent BioSolutions deal

Emergent acquired Evolva’s EV-035 antibiotic portfolio, including preclinical melioidosis candidate GC-072 . The U.S. Department of Defense’s Defense Threat Reduction Agency is funding preclinical development of GC-072 under a 2014 contract with Evolva. The government...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Evolva Holding, U.S. Department of Defense infectious news

Evolva received a $6.5 million contract from the DoD’s Defense Threat Reduction Agency (DTRA) to fund the first 15-month stage of preclinical development for GC-072, a broad-spectrum antibiotic. GC-072 is the lead compound in Evolva’s...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

Evolva Holding infectious news

Evolva said the U.S. Defense Threat Reduction Agency selected the biotech to enter into contract negotiations for potential preclinical funding of up to $14.7 million to develop GC-072. Evolva said the negotiations are expected to...
07:00 , Sep 17, 2012 |  BC Week In Review  |  Clinical News

Evolva Holding preclinical data

In a mouse model of melioidosis, analogs of EV-035 led to 21-day survival rates of 87.5% when given alone and 75% when given in combination with ceftazidime vs. 12.5% for vehicle-treated controls. In mice challenged...